According to a recent LinkedIn post from Circulate, CEO Dr. Brad Younggren is speaking at the Longevity SD Summit 2026 in San Diego on the topic “From Research to Clinic: Therapeutic Plasma Exchange in the Longevity Era.” The post highlights that his talk examines how Therapeutic Plasma Exchange, or TPE, a long-standing hospital therapy, is being introduced into the outpatient longevity market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that Circulate is positioning itself at the intersection of established clinical practice and emerging longevity science, emphasizing TPE’s potential effects on inflammation, immune dysfunction, and age-related decline. For investors, this public focus may indicate a strategic push toward commercializing TPE-based offerings in preventive and healthy aging care models.
By aligning with a high-visibility longevity conference, Circulate appears to be targeting thought-leader engagement and validation within a niche but growing segment of healthspan-focused interventions. If the company can translate this scientific and clinical positioning into scalable outpatient services, it could tap into rising demand for longevity treatments and potentially strengthen its competitive standing in the broader healthcare innovation space.